Page last updated: 2024-10-22

amifostine anhydrous and Salivary Gland Neoplasms

amifostine anhydrous has been researched along with Salivary Gland Neoplasms in 1 studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.

Research Excerpts

ExcerptRelevanceReference
"28 patients with squamous cell carcinomas of the head and neck received adjunctive or primary radiotherapy (5 days per week with daily fractions of 2 Gy, up to a total dose of 60 Gy) in conjunction with carboplatin (70 mg/m2) on days 1-5 and days 21-26."2.70Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. ( Bennett, CL; Buntzel, J; Glatzel, M; Lane, D; Stinson, T, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bennett, CL1
Lane, D1
Stinson, T1
Glatzel, M1
Buntzel, J1

Trials

1 trial available for amifostine anhydrous and Salivary Gland Neoplasms

ArticleYear
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Cancer investigation, 2001, Volume: 19, Issue:2

    Topics: Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy;

2001